New combo therapy shows promise for tough lung cancers
NCT ID NCT04701307
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This study tests two drugs—niraparib and dostarlimab—together in people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a repair process in cancer cells, while dostarlimab helps the immune system attack them. The goal is to see if this combination can slow or stop the cancer from growing. About 48 adults are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.